Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with ...

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study. Dr. James E. Hoffman is a co-author. Serious ...

Sanofi’s new multiple myeloma drug Sarclisa (isatuximab ... Sanofi used to be a major player in cancer when chemotherapy was standard of care, but has not kept pace with immunotherapy ...

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma ... cancer that have responded to platinum chemotherapy. Early results from the phase 3 ...

Multiple myeloma is a cancer that affects a ... useful cells to the bone marrow before it is infused into a patient. Chemotherapy – Myeloma treatment generally involves anticancer drugs, which enter ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...